See Article by Jordan et al Anthracycline-based chemotherapy regimens remain in wide use for treatment of many malignancies, despite the rapid growth and development of targeted pathway inhibitors and immunotherapies (both of which can be associated with a variety of cardiovascular toxicities). Discovered in the late 1960s and commonly used as a chemotherapeutic in the early 1970s, anthracycline cardiotoxicity was quickly recognized as a serious complication1,2 and served as the canonical example of chemotherapy-associated cardiomyopathy, spurring the development of the field of cardio-oncology. The observation that left ventricular (LV) mass and growth potential are reduced after exposure to anthracycline chemotherapy was first observed in survivors of childhood cancer and the term Grinch Syndrome was coined by Lipshultz et al3 to describe the potential evolution of reduced LV mass after anthracycline therapy to a restrictive cardiomyopathy in some patients. In adults, a reduction in LV mass has been observed several years after anthracycline-based chemotherapy and is associated with increased cardiac events.4 In this issue of Circulation: Heart Failure , Jordan et al5 provide further details to our understanding of how anthracycline chemotherapy alters cardiac structure and function, using serial cardiac magnetic resonance imaging in a cohort of …

中文翻译：

---

蒽环类心肌病

尽管靶向通路抑制剂和免疫疗法的快速发展和发展（两者都可能与多种心血管毒性有关），但基于蒽环类的化疗方案仍广泛用于治疗许多恶性肿瘤。蒽环类药物的心脏毒性在1960年代末期发现，并在1970年代初通常用作化学治疗剂，很快被认为是一种严重的并发症1,2，并成为化学疗法相关性心肌病的典型例子，从而刺激了心血管疾病领域的发展。首次在儿童癌症幸存者中观察到蒽环类药物化疗后左心室（LV）质量和生长潜能降低的观察结果，Lipshultz等人[3]创造了“格林奇综合症”一词来描述蒽环类药物治疗后左室质量降低的潜在演变对某些患者的限制性心肌病。在成年人中，基于蒽环类药物的化疗后几年观察到左室重量减少，并且与心脏事件增加有关。4在本期《循环：心力衰竭》中，Jordan等[5]为我们对蒽环类药物如何改变的理解提供了进一步的细节。心脏结构和功能，在...队列中使用连续心脏磁共振成像